Search Result

Results for "

Janus kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	JAK (28) Apoptosis (2) CDK (2) EGFR (1) FLT3 (2) GSK-3 (1) IGF-1R (1) Isotope-Labeled Compounds (1) Microtubule/Tubulin (1) PI3K (1) Protease Activated Receptor (PAR) (1) STAT (3)
By Research Areas:	Cancer (12) Cardiovascular Disease (1) Endocrinology (1) Infection (2) Inflammation/Immunology (17)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: JAK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N2521

Tetramethylcurcumin FLLL31	STAT Apoptosis	Inflammation/Immunology Cancer
Tetramethylcurcumin (FLLL31), derived from curcumin, specifically suppresses the phosphorylation of STAT3 by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain. Tetramethylcurcumin exhibits anti-inflammatory and anti-cancer effects .

HY-148785

Nimucitinib	JAK	Others
Nimucitinib is a Janus kinase (JAK) inhibitor .

HY-148791

Pumecitinib PG-011	JAK	Inflammation/Immunology Cancer
Pumecitinib is a **Janus kinase (JAK**) inhibitor with anti-inflammatory activity .

HY-101976

JAK3-IN-6	JAK	Inflammation/Immunology
JAK3-IN-6 is a potent, selective irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC₅₀ of 0.15 nM.

HY-156621

Lepzacitinib	JAK	Inflammation/Immunology
Lepzacitinib is a Janus kinase inhibitor targeting to JAK 1/3. Lepzacitinib exhibits anti-inflammatory effect and inhibits atopic dermatitis and other skin diseases .

HY-159827

Cenacitinib	JAK	Inflammation/Immunology
Cenacitinib is a potent **Janus kinase** inhibitor. Cenacitinib shows anti-inflammatory activity .

HY-159536

Frevecitinibum Frevecitinib	JAK	Cancer
Frevecitinibum (Frevecitinib) is a Janus kinase inhibitor, with anti-inflammatory effect .

HY-153701S

Envudeucitinibum Envudeucitinib	JAK	Inflammation/Immunology
Envudeucitinibum (Envudeucitinib) is a Janus kinase inhibitor, with anti-inflammatory effect .

HY-159528

Girocitinibum Girocitinib	JAK	Inflammation/Immunology
Girocitinibum (Girocitinib) is a Janus kinase inhibitor, with anti-inflammatory effect .

HY-169184

GDC-9918	JAK	Cancer
GDC-9918 (compund GDC-9918) is a *Janus* kinase inhibitor .

HY-163653

Zemprocitinib	JAK	Cancer
Zemprocitinib (Compound 1) is a Janus kinase (JAK) inhibitor. The IC₅₀ values for JAK1, JAK2 and TYK2 are 5.95, 141.3 and 119 nM, respectively .

HY-119935

JAK3 covalent inhibitor-1	JAK	Inflammation/Immunology
JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC₅₀ of 11 nM and shows 246-fold selectivity vs other JAKs .

HY-132849

Nezulcitinib TD-0903	JAK	Infection Inflammation/Immunology
Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation .

HY-161259

JAK-IN-36	JAK	Inflammation/Immunology
JAK-IN-36 (Compound 12e) is a potent and selective inhibitor of Janus Kinase 1 (JAK1) with a IC₅₀ value of 2.2 nM. JAK-IN-36 can be used in the study of autoimmune diseases .

HY-151258

TK4g	JAK	Cancer
TK4g is a **Janus kinase (JAK) inhibitor with the IC₅₀** values of 12.61 nM and 15.80 nM for JAK2 and JAK3, respectively. TK4g can be used in lymphoid-derived diseases and leukemia cancer research .

HY-151259

TK4b	JAK	Cancer
TK4b is a **Janus kinase (JAK) inhibitor with the IC₅₀** values of 19.40 nM and 18.42 nM for JAK2 and JAK3, respectively. TK4b can be used in lymphoid-derived diseases and leukemia cancer research .

HY-156423

Tubulin/JAK2-IN-1	Microtubule/Tubulin JAK	Cancer
Tubulin/JAK2-IN-1 (compound 7g) is a dual inhibitor of Janus kinase 2 (JAK2) and microtubule. Tubulin/JAK2-IN-1 has potent antiproliferative activity against the cancer cells .

HY-112708

Brepocitinib 3 Publications Verification PF-06700841	JAK	Inflammation/Immunology
Brepocitinib (PF-06700841) is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC₅₀s of 17 nM and 23 nM, respectively. Brepocitinib also inhibits JAK2 and JAK3 with IC₅₀s of 77 nM and 6.49 μM, respectively .

HY-112708A

Brepocitinib P-Tosylate 3 Publications Verification PF-06700841 P-Tosylate	JAK	Inflammation/Immunology
Brepocitinib (PF-06700841) P-Tosylate is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC₅₀s of 17 nM and 23 nM, respectively. Brepocitinib P-Tosylate also inhibits JAK2 and JAK3 with IC₅₀s of 77 nM and 6.49 μM, respectively .

HY-W740378

1,2,3,4-Tetrahydro Staurosporin AFN-941	Others	Others
1,2,3,4-Tetrahydrostaurosporine is a derivative of Staurosporine (HY-15141) and an inhibitor of mutant EGFR (IC₅₀=74 nM for EGFRT790M). It is selective for EGFRT790M over wild-type EGFR (IC₅₀=390 nM). It also binds to Janus kinase 3 (JAK3).

HY-125019

iJak-381	JAK STAT	Inflammation/Immunology
iJak-381 is a JAK1/2 inhibitor with anti-inflammatory activity. iJak-381 blocks IL-13 signaling and also inhibits IL-4 and IL-6 signaling pathways. iJak-381 also reduced p-STAT6 levels and inhibited the influx of inflammatory cells into the lungs of mice. iJak-381 inhibits airway hyperresponsiveness (AHR) .

HY-149257

HAT-SIL-TG-1&AT	JAK STAT	Cancer
HAT-SIL-TG-1&AT is a **Janus tyrosine kinase (JAK) inhibitor with antitumor effects. HAT-SIL-TG-1&AT is the hypoxia-activated prodrug, witch inhibits JAK-STAT signaling in tumor tissue. And HAT-SIL-TG-1&AT inhibits HEL cells proliferation and downregulated phosphorylated STAT3/5** under hypoxic conditions .

HY-19569

Upadacitinib Maximum Cited Publications 12 Publications Verification ABT-494	JAK	Inflammation/Immunology
Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .

HY-19569A

Upadacitinib tartrate tetrahydrate ABT-494 tartrate tetrahydrate	JAK	Inflammation/Immunology
Upadacitinib (ABT-494) tartrate tetrahydrate is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib tartrate tetrahydrate displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib tartrate tetrahydrate can be used for several autoimmune disorders research .

HY-P10373

pJAK2(1001–1013)	JAK	Infection
pJAK2(1001-1013) is a SOCS1/3 antagonist. pJAK2(1001–1013) plays a positive role in antiviral immune response by inhibiting the negative regulatory effect of SOCS proteins and enhancing the JAK/STAT signaling pathway

HY-161618

MJ04	JAK EGFR PI3K IGF-1R GSK-3	Inflammation/Immunology Endocrinology
MJ04 is a selective inhibitor for Janus Kinase 3 (JAK 3) with an IC₅₀ of 2.03 nM. MJ04 inhibits T cell differentation and inhibits the proinfammatory cytokines in Lipopolysaccharides (HY-D1056)‑induced macrophages. MJ04 exhibits good pharmacokinetic characters in mice, promotes hair growth in DHT-induced androgenetic alopecia (AGA) in athymic mice model, without significant toxicity (LD₅₀ >2 g/kg) .

HY-19569R

Upadacitinib (Standard) ABT-494 (Standard)	JAK	Inflammation/Immunology
Upadacitinib (Standard) is the analytical standard of Upadacitinib. This product is intended for research and analytical applications. Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .

HY-15163

Zotiraciclib TG02; SB1317	JAK CDK FLT3	Cancer
Zotiraciclib (TG02) is an orally active potent inhibitor of CDK2, JAK2 and FLT3 with IC₅₀ values of 13, 73, and 56 nM, respectively. Zotiraciclib can be used for the research of advanced leukemias and multiple myeloma .

HY-15163A

Zotiraciclib hydrochloride	FLT3 JAK CDK	Cancer
Zotiraciclib hydrochloride is a novel small molecule multi-target enzyme inhibitor with activity in inhibiting tumor growth. Zotiraciclib hydrochloride exerts its anti-tumor effect by reducing the level of Myc through inhibiting cyclin-dependent kinase 9 (CDK9). Zotiraciclib hydrochloride may be useful for inhibiting cancers that cross the blood-brain barrier. The high protein level of MCL-1 of Zotiraciclib hydrochloride is associated with survival, suggesting that it may serve as a prognostic factor and inhibitory target in further studies .

HY-18200A

Atopaxar hydrochloride E5555 hydrochloride; ER-172594-00 hydrochloride	Protease Activated Receptor (PAR) JAK Apoptosis	Cardiovascular Disease Cancer
Atopaxar hydrochloride (E5555 hydrochloride) is the hydrochloride salt form of Atopaxar (HY-18200). Atopaxar hydrochloride is an orally active, selective and reversible antagonist for thrombin receptor protease-activated receptor-1 (PAR-1). Atopaxar hydrochloride is the inhibitor for Janus kinase 1 (JAK1) and JAK2, which inhibits the JAK-STAT with EC₅₀ of 5.90 μM in A549. Atopaxar hydrochloride inhibits the cell viability of A549 (IC₅₀=7.02 μM), arrests the cell cycle at G1 phase and induces apoptosis. Atopaxar hydrochloride exhibits antiplatelet and antitumor activities. Atopaxar hydrochloride can be used for the research of atherothrombotic disease .

HY-W727879

Upadacitinib-15N,d2 ABT-494-¹⁵N,d₂	Isotope-Labeled Compounds	Others
Upadacitinib- ¹⁵N,d₂ (ABT-494- ¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- ¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib- ¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- ¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research .

Cat. No.	Product Name

HY-L008

JAK/STAT Compound Library	471 compounds
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID). MCE provides 471 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

JAK/STAT Compound Library

471 compounds

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID).

MCE provides 471 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

Cat. No.	Product Name	Target	Research Area

HY-P10373

pJAK2(1001–1013)	JAK	Infection
pJAK2(1001-1013) is a SOCS1/3 antagonist. pJAK2(1001–1013) plays a positive role in antiviral immune response by inhibiting the negative regulatory effect of SOCS proteins and enhancing the JAK/STAT signaling pathway

Tetramethylcurcumin FLLL31	Structural Classification other families Classification of Application Fields Source classification Phenols Plants Inflammation/Immunology Disease Research Fields	STAT Apoptosis
Tetramethylcurcumin (FLLL31), derived from curcumin, specifically suppresses the phosphorylation of STAT3 by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain. Tetramethylcurcumin exhibits anti-inflammatory and anti-cancer effects .

Species:	Human (7)
Tag:	His (5) Tag Free (1) GST (1)
Source:	Sf9 insect cells (2) P. pastoris (2) E. coli (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P7989

	Janus kinase 2/JAK2 Protein, Human (His) JAK2, Janus kinase 2	Human	E. coli
	Janus kinase 2/JAK2 Protein, Human (His) is a recombinant human JAK2 expressed in E. coli with a His tag at the N-terminus. JAK2 is a non-receptor tyrosine kinase.

HY-P701102

	Janus kinase 2/JAK2 Protein, Human (381aa, His) JAK 2; JAK-2; JAK2; JAK2_HUMAN; Janus Activating kinase 2; Janus kinase 2 (a protein tyrosine kinase); Janus kinase 2; JTK 10; JTK10; kinase Jak2; OTTHUMP00000043260; THCYT3; Tyrosine protein kinase JAK2; Tyrosine-protein kinase JAK2	Human	E. coli
	Janus kinase 2/JAK2 Protein, Human is a recombinant human JAK2 expressed in E. coli with a His tag at the N-terminus. JAK2 is a non-receptor tyrosine kinase.

HY-P700583

	JAK1 Protein, Human (P. pastoris, His) JAK1; JAK1A; JAK1B; Tyrosine-protein kinase JAK1; Janus kinase 1; JAK-1	Human	P. pastoris
	JAK1 protein is a non-receptor tyrosine kinase that plays a crucial role in IFN-α/β/γ signaling and serves as a kinase partner for IL-2 and IL-10 receptors. It cooperates with the type I interferon receptor IFNAR2 to phosphorylate and activate IFNAR2 upon interferon binding to IFNAR1-IFNAR2. JAK1 Protein, Human (P. pastoris, His) is the recombinant human-derived JAK1 protein, expressed by P. pastoris , with N-6*His labeled tag. The total length of JAK1 Protein, Human (P. pastoris, His) is 305 a.a., with molecular weight of 36.9 kDa.

HY-P702720

	Janus kinase 2/JAK2 Protein, Human (sf9) JAK2; Janus kinase 2; tyrosine-protein kinase JAK2; JTK10; JAK-2; Janus kinase 2 (a protein tyrosine kinase); THCYT3	Human	Sf9 insect cells
	The Janus kinase 2 (JAK2) protein is a critical non-receptor tyrosine kinase that drives important cellular processes affecting growth, development, differentiation, and histone modifications. JAK2 plays a role in innate and adaptive immunity, interacting with receptors such as growth hormone, erythropoietin, and interleukins. Janus kinase 2/JAK2 Protein, Human (sf9) is the recombinant human-derived Janus kinase 2/JAK2, expressed by Sf9 insect cells , with tag Free labeled tag. ,

HY-P702721

	JAK3 Protein, Human (sf9, GST) JAK3; Janus kinase 3; tyrosine-protein kinase JAK3; JAK 3; JAK3_HUMAN; JAKL; L JAK; leukocyte Janus kinase; LJAK; tyrosine protein kinase JAK3; Janus kinase 3 (a protein tyrosine kinase, leukocyte); JAK-3; L-JAK	Human	Sf9 insect cells
	JAK3 Protein, Human (sf9, GST) is the recombinant human-derived JAK3, expressed by Sf9 insect cells , with GST labeled tag. ,

HY-P790065

	JAK3 Protein, Human (His) Leukocyte Janus kinase (L-JAK); JAK3	Human	E. coli
	JAK3 Protein, Human (His) is the recombinant human-derived JAK3, expressed by E. coli , with C-6*His labeled tag. ,

HY-P71785

	SOCS1 Protein, Human (P.pastoris, His) CISH 1; CISH1; Cytokine inducible SH2 protein 1; JAB; JAK binding protein; JAK-binding protein; Janus kinase binding protein ; SOCS 1; TEC interacting protein 3; Tec-interacting protein 3; TIP 3	Human	P. pastoris
	The SOCS1 protein is an important negative regulator that inhibits type I and type II interferon signaling as well as cytokines such as IL2, IL4, IL6, and LIF. It downregulates the signaling of the JAK/STAT pathway by inhibiting JAK proteins and IFNGR1. SOCS1 Protein, Human (P.pastoris, His) is the recombinant human-derived SOCS1 protein, expressed by P. pastoris , with N-His labeled tag. The total length of SOCS1 Protein, Human (P.pastoris, His) is 211 a.a., with molecular weight of ~25.6 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-W727879

Upadacitinib-15N,d2

Upadacitinib- ¹⁵N,d₂ (ABT-494- ¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- ¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib- ¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- ¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research .

HY-153701S

Envudeucitinibum
Envudeucitinibum (Envudeucitinib) is a Janus kinase inhibitor, with anti-inflammatory effect .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80727

	JAK2 Antibody (YA330) JAK2; Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	WB	Human, Mouse
	JAK2 Antibody (YA330) is a non-conjugated and Rabbit origined monoclonal antibody about 131 kDa, targeting to JAK2. It can be used for WB assays with tag free, in the background of Human, Mouse.

HY-P80829

	Phospho-JAK2 (Tyr1007/1008) Antibody JAK2; Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse, Rat
	Phospho-JAK2 (Tyr1007/1008) Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 131 kDa, targeting to Phospho-JAK2 (Tyr1007/1008). It can be used for WB,IHC-P,ICC/IF,IP,FC assays with tag free, in the background of Human, Mouse, Rat.

HY-P80726

	JAK1 Antibody (YA722) JAK1; JAK1A; JAK1B; Tyrosine-protein kinase JAK1; Janus kinase 1; JAK-1	WB, ICC/IF, IP	Human, Rat
	JAK1 Antibody (YA722) is a non-conjugated and Mouse origined monoclonal antibody about 133 kDa, targeting to JAK1 (8B8). It can be used for WB,ICC/IF,IP assays with tag free, in the background of Human, Rat.

HY-P82721

	JAK3 Antibody (YA2466) JAK3; Tyrosine-protein kinase JAK3; Janus kinase 3; JAK-3; Leukocyte Janus kinase; L-JAK	WB, ICC/IF	Human
	JAK3 Antibody (YA2466) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2466), targeting JAK3, with a predicted molecular weight of 125 kDa (observed band size: 125 kDa). JAK3 Antibody (YA2466) can be used for WB, ICC/IF experiment in human background.